Skip to content

Effectiveness of Yoga in Atopic Dermatitis

Effectiveness of add-on Yoga therapy compared to standard care on Severity of disease and Quality of Life in individuals with Atopic Dermatitis at tertiary care hospital in Rishikesh, Uttarakhand: A Pilot study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074653
Enrollment
100
Registered
2024-10-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Yoga therapy & Standard care: 1. Laghu Sankha Prakshalana (LSP) 2. Cyclic meditation with Standard care which includes liberal emollients, topical steroids, anti-histamines. Schedule

Sponsors

CCRYN
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly Diagnosed cases of Atopic dermatitis Age: =18-60 years Residence: Uttarakhand Individuals who are willing to provide informed consent. Individuals with access to smartphones with internet connection.

Exclusion criteria

Exclusion criteria: Individuals with other skin conditions that could confound the assessment of eczema, such as psoriasis or infections Individuals with co-morbidities e.g. diabetes, autoimmune diseases, cardiovascular disorders, joint disorders, deformities, hypertension, hernia, peptic ulcers, coronary artery disease, chronic renal failure, Anal fissures Pregnant women Females during menstruation as it is contraindicated during yoga intervention. Weak and debilitated patients Individuals with significant cognitive impairments that may hinder their ability to follow instructions during yoga sessions

Design outcomes

Primary

MeasureTime frame
EASI scoresTimepoint: Day 0, Day 30/Termination of trial

Secondary

MeasureTime frame
Blood eosinophilsTimepoint: Day 0, Day 30/Termination of trial;C-reactive proteinTimepoint: Day 0, Day 30/Termination of trial;DLQI scores Timepoint: Day 0, Day 30/Termination of trial;Neutrophil Lymphocyte ratioTimepoint: Day 0, Day 30/Termination of trial;NF?BTimepoint: Day 0, Day 30/Termination of trial;Serum cytokines - CCL17/TARC, IL31 Timepoint: Day 0, Day 30/ Termination of trial;Serum IgETimepoint: Day 0, day 30/Termination of trial

Countries

India

Contacts

Public ContactDr Vartika Saxena

AIIMS, Rishikesh

vartika.cfm@aiimsrishikesh.edu.in8475000294

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026